Search
for
Did you mean Upper Respiratory Infections?
Sort by
Research 30 of 1000+
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Baricitinib for the Treatment of Alopecia Areata
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Adverse effects of baricitinib in comparison to methotrexate in the treatment of severe alopecia areata
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- EPH39 Alopecia Areata: Targeted Review of Adverse Events Associated with Clinical Studies of Treatments
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Zinc in hair and urine of paediatric patients
- COVID-19 VIRUS-POSITIVE PATIENTS AFTER LARINGECTOMY: TREATMENT IN A HOSPITAL
- NEUROMA DE NERVO RADIAL APÓS CORREÇÃO CIRÚRGICA DA LESÃO SECUNDÁRIA DE FRATURA DIAFISÁRIA DE ÚMERO
- Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
- Classic Sweet sydrome: A case report
- Janus kinase inhibitors in dermatology: A systematic review
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Off-label dermatologic uses of IL-23 inhibitors
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
- Novel investigational drugs for alopecia areata and future perspectives
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Safety and Efficacy of Bimatoprost Solution 0.03% Topical Application in Patients with Chemotherapy-Induced Eyelash Loss
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study